Copyright Reports & Markets. All rights reserved.

Global Remicade (infliximab) Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Remicade (infliximab) Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Remicade (infliximab) Drug Market Size Growth Rate by Product
      • 1.4.2 Brands Drugs
      • 1.4.3 Generic Drugs
    • 1.5 Market by End User
      • 1.5.1 Global Remicade (infliximab) Drug Market Size Growth Rate by End User
      • 1.5.2 Crohn's Disease
      • 1.5.3 Pediatric Crohn's Disease
      • 1.5.4 Ulcerative Colitis
      • 1.5.5 Pediatric Ulcerative Colitis
      • 1.5.6 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Remicade (infliximab) Drug Market Size
      • 2.1.1 Global Remicade (infliximab) Drug Revenue 2014-2025
      • 2.1.2 Global Remicade (infliximab) Drug Sales 2014-2025
    • 2.2 Remicade (infliximab) Drug Growth Rate by Regions
      • 2.2.1 Global Remicade (infliximab) Drug Sales by Regions
      • 2.2.2 Global Remicade (infliximab) Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Remicade (infliximab) Drug Sales by Manufacturers
      • 3.1.1 Remicade (infliximab) Drug Sales by Manufacturers
      • 3.1.2 Remicade (infliximab) Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Remicade (infliximab) Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Remicade (infliximab) Drug Revenue by Manufacturers
      • 3.2.1 Remicade (infliximab) Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Remicade (infliximab) Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Remicade (infliximab) Drug Price by Manufacturers
    • 3.4 Remicade (infliximab) Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Remicade (infliximab) Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Remicade (infliximab) Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Remicade (infliximab) Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Remicade (infliximab) Drug Sales by Product
    • 4.2 Global Remicade (infliximab) Drug Revenue by Product
    • 4.3 Remicade (infliximab) Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Remicade (infliximab) Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Remicade (infliximab) Drug by Countries
      • 6.1.1 North America Remicade (infliximab) Drug Sales by Countries
      • 6.1.2 North America Remicade (infliximab) Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Remicade (infliximab) Drug by Product
    • 6.3 North America Remicade (infliximab) Drug by End User

    7 Europe

    • 7.1 Europe Remicade (infliximab) Drug by Countries
      • 7.1.1 Europe Remicade (infliximab) Drug Sales by Countries
      • 7.1.2 Europe Remicade (infliximab) Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Remicade (infliximab) Drug by Product
    • 7.3 Europe Remicade (infliximab) Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Remicade (infliximab) Drug by Countries
      • 8.1.1 Asia Pacific Remicade (infliximab) Drug Sales by Countries
      • 8.1.2 Asia Pacific Remicade (infliximab) Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Remicade (infliximab) Drug by Product
    • 8.3 Asia Pacific Remicade (infliximab) Drug by End User

    9 Central & South America

    • 9.1 Central & South America Remicade (infliximab) Drug by Countries
      • 9.1.1 Central & South America Remicade (infliximab) Drug Sales by Countries
      • 9.1.2 Central & South America Remicade (infliximab) Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Remicade (infliximab) Drug by Product
    • 9.3 Central & South America Remicade (infliximab) Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Remicade (infliximab) Drug by Countries
      • 10.1.1 Middle East and Africa Remicade (infliximab) Drug Sales by Countries
      • 10.1.2 Middle East and Africa Remicade (infliximab) Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Remicade (infliximab) Drug by Product
    • 10.3 Middle East and Africa Remicade (infliximab) Drug by End User

    11 Company Profiles

    • 11.1 Janssen
      • 11.1.1 Janssen Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Janssen Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Janssen Remicade (infliximab) Drug Products Offered
      • 11.1.5 Janssen Recent Development
    • 11.2 Hospira
      • 11.2.1 Hospira Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Hospira Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Hospira Remicade (infliximab) Drug Products Offered
      • 11.2.5 Hospira Recent Development
    • 11.3 Celltrion Healthcare
      • 11.3.1 Celltrion Healthcare Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Celltrion Healthcare Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Celltrion Healthcare Remicade (infliximab) Drug Products Offered
      • 11.3.5 Celltrion Healthcare Recent Development
    • 11.4 Epirus Biopharmaceuticals
      • 11.4.1 Epirus Biopharmaceuticals Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Epirus Biopharmaceuticals Remicade (infliximab) Drug Products Offered
      • 11.4.5 Epirus Biopharmaceuticals Recent Development
    • 11.5 Samsung Bioepsis
      • 11.5.1 Samsung Bioepsis Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Samsung Bioepsis Remicade (infliximab) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Samsung Bioepsis Remicade (infliximab) Drug Products Offered
      • 11.5.5 Samsung Bioepsis Recent Development

    12 Future Forecast

    • 12.1 Remicade (infliximab) Drug Market Forecast by Regions
      • 12.1.1 Global Remicade (infliximab) Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Remicade (infliximab) Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Remicade (infliximab) Drug Market Forecast by Product
      • 12.2.1 Global Remicade (infliximab) Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Remicade (infliximab) Drug Revenue Forecast by Product 2019-2025
    • 12.3 Remicade (infliximab) Drug Market Forecast by End User
    • 12.4 North America Remicade (infliximab) Drug Forecast
    • 12.5 Europe Remicade (infliximab) Drug Forecast
    • 12.6 Asia Pacific Remicade (infliximab) Drug Forecast
    • 12.7 Central & South America Remicade (infliximab) Drug Forecast
    • 12.8 Middle East and Africa Remicade (infliximab) Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Remicade (infliximab) Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
      The global Remicade (infliximab) Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Remicade (infliximab) Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Remicade (infliximab) Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Remicade (infliximab) Drug in these regions.
      This research report categorizes the global Remicade (infliximab) Drug market by top players/brands, region, type and end user. This report also studies the global Remicade (infliximab) Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Janssen
      Hospira
      Celltrion Healthcare
      Epirus Biopharmaceuticals
      Samsung Bioepsis

      Market size by Product
      Brands Drugs
      Generic Drugs
      Market size by End User
      Crohn's Disease
      Pediatric Crohn's Disease
      Ulcerative Colitis
      Pediatric Ulcerative Colitis
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Remicade (infliximab) Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Remicade (infliximab) Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Remicade (infliximab) Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Remicade (infliximab) Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Remicade (infliximab) Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Remicade (infliximab) Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now